Sc. Raghavan et al., Analysis of the V(D)J recombination efficiency at lymphoid chromosomal translocation breakpoints, J BIOL CHEM, 276(31), 2001, pp. 29126-29133
Chromosomal translocations and deletions are among the major events that in
itiate neoplasia. For lymphoid chromosomal translocations, misrecognition b
y the RAG (recombination activating gene) complex of V(D)J recombination is
one contributing factor that has long been proposed. The chromosomal trans
locations involving LMO2 (t(11;14)(p13;q11)), Ttg-1 (t(11;14)(p15;q11)), an
d Hox11 (t(10;14)(q24;q11)) are among the clearest examples in which it app
ears that a D or J segment has synapsed with an adventitious heptamer/nonam
er at a gene outside of one of the antigen receptor loci. The interstitial
deletion at 1p32 involving SIL (SCL-interrupting locus)/SCL (stem cell leuk
emia) is a case involving two non-V(D)J sites that have been suggested to b
e V(D)J recombination mistakes. Here we have used our human extrachromosoma
l substrate assay to formally test the hypothesis that these regions are V(
D)J recombination misrecognition sites and, more importantly, to quantify t
heir efficiency as V(D)J recombination targets within the cell. We find tha
t the LMO2 fragile site functions as a 12-signal at an efficiency that is o
nly 27-fold lower than that of a consensus 12-signal. The Ttg-1 site functi
ons as a 23-signal at an efficiency 530-fold lower than that of a consensus
23-signal. Hox11 failed to undergo recombination as a 12. or 23-signal and
was at least 20,000-fold less efficient than consensus signals. SIL has be
en predicted to function as a 12-signal and SCL as a 23-signal. However, we
find that SH, actually functions as a 23-signal. These results provide a f
ormal demonstration that certain chromosomal fragile sites can serve as RAG
complex targets, and they determine whether these sites function as 12- ve
rsus 23-signals. These results quantify one of the three major factors that
determine the frequency of these translocations in T-cell acute lymphocyti
c leukemia.